Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses

被引:13
作者
Auclair, B [1 ]
Ducharme, MP [1 ]
机构
[1] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada
关键词
D O I
10.1128/AAC.43.6.1465
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A population pharmacokinetic (PK) analysis was conducted to determine if piperacillin and tazobactam exhibited linear or nonlinear pgs and if incremental changes in the daily dosage of piperacillin affected tazobactam PKs. Four dosage groups were evaluated after multiple dosing regimens. Concentrations of drug in plasma and amounts in urine were best fitted by using a linear two-compartment PK model. No significant difference between dosing groups was seen for any piperacillin or tazobactam PI( parameters. Both drugs exhibited linear PKs when given at usual clinical doses. Tazobactam PKs did not appear to be affected by the different dosing regimens of piperacillin.
引用
收藏
页码:1465 / 1468
页数:4
相关论文
共 30 条
[1]  
AKALKE H, 1992, BIOMETRIKA, V66, P237
[2]   THE EFFECT OF PIPERACILLIN DOSE ON ELIMINATION KINETICS IN RENAL IMPAIRMENT [J].
ARONOFF, GR ;
SLOAN, RS ;
BRIER, ME ;
LUFT, FC .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (04) :543-547
[3]  
BATRA VK, 1979, CLIN PHARMACOL THER, V26, P41
[4]   DOSE DEPENDENCE OF PIPERACILLIN PHARMACOKINETICS [J].
BERGAN, T ;
WILLIAMS, JD .
CHEMOTHERAPY, 1982, 28 (03) :153-159
[5]  
COLLINS D, 1995, IT2S USERS GUIDE
[6]  
DARGENIO DZ, 1992, DAPT 2 USERS GUIDE
[7]   PHARMACOKINETICS OF PIPERACILLIN FOLLOWING INTRAVENOUS ADMINISTRATION [J].
EVANS, MAL ;
WILSON, P ;
LEUNG, T ;
WILLIAMS, JD .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1978, 4 (03) :255-261
[8]  
EVANS MLA, 1979, DRUGS EXP CLIN RES, V5, P111
[9]  
Gibaldi M. P., 1982, PHARMACOKINETICS
[10]   SINGLE-DOSE PHARMACOKINETICS OF PIPERACILLIN AND TAZOBACTAM IN PATIENTS WITH RENAL-DISEASE [J].
JOHNSON, CA ;
HALSTENSON, CE ;
KELLOWAY, JS ;
SHAPIRO, BE ;
ZIMMERMAN, SW ;
TONELLI, A ;
FAULKNER, R ;
DUTTA, A ;
HAYNES, J ;
GREENE, DS ;
KUYE, O .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (01) :32-41